Recent Advances for Confident Cell Line Transfer

Early stability prediction methods enable faster and safer clone selection in cell line development, reducing risk and shortening time to market by predicting clone instability up to four weeks earlier1.

Proprietary expression platforms such as CHEF1™ offer proven reliability, helping ensure consistent, high-quality cell lines for pharmaceutical manufacturing1.

Reproducible, high-yield cell line development can now be achieved with advanced electroporation platforms, like MaxCyte, which provide robust transfection for various cell types and facilitate rapid manufacturing of engineered cells, including for therapies such as non-viral CAR T5.

Maintaining Good Manufacturing Practice (GMP) compliance from the start of cell therapy development helps mitigate clinical risks related to cell line transfer and enhances confidence in regulatory submissions and product safety5.

Sources:

1. https://www.agcbio.com/case-studies/chef1-cell-line-develoment-stability-evaluations-clone-selection

5. https://maxcyte.com/news/maxcyte-minutes-newsletter-q1-2025/